GENI vs. ENFN, CSGS, PDFS, GOGO, ICHR, INFN, OPRA, HLIT, ANGI, and BASE
Should you be buying Genius Sports stock or one of its competitors? The main competitors of Genius Sports include Enfusion (ENFN), CSG Systems International (CSGS), PDF Solutions (PDFS), Gogo (GOGO), Ichor (ICHR), Infinera (INFN), Opera (OPRA), Harmonic (HLIT), Angi (ANGI), and Couchbase (BASE). These companies are all part of the "computer and technology" sector.
Genius Sports (NYSE:GENI) and Enfusion (NYSE:ENFN) are both small-cap computer and technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, community ranking, valuation, dividends, risk and institutional ownership.
In the previous week, Genius Sports had 9 more articles in the media than Enfusion. MarketBeat recorded 20 mentions for Genius Sports and 11 mentions for Enfusion. Genius Sports' average media sentiment score of 0.30 beat Enfusion's score of 0.10 indicating that Genius Sports is being referred to more favorably in the media.
Genius Sports presently has a consensus target price of $9.33, indicating a potential upside of 70.32%. Enfusion has a consensus target price of $9.33, indicating a potential downside of 0.92%. Given Genius Sports' stronger consensus rating and higher probable upside, research analysts clearly believe Genius Sports is more favorable than Enfusion.
Genius Sports received 43 more outperform votes than Enfusion when rated by MarketBeat users. Likewise, 62.65% of users gave Genius Sports an outperform vote while only 18.75% of users gave Enfusion an outperform vote.
81.9% of Genius Sports shares are held by institutional investors. Comparatively, 81.1% of Enfusion shares are held by institutional investors. 16.6% of Genius Sports shares are held by company insiders. Comparatively, 39.2% of Enfusion shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Enfusion has lower revenue, but higher earnings than Genius Sports. Genius Sports is trading at a lower price-to-earnings ratio than Enfusion, indicating that it is currently the more affordable of the two stocks.
Genius Sports has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500. Comparatively, Enfusion has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500.
Enfusion has a net margin of 1.40% compared to Genius Sports' net margin of -19.73%. Enfusion's return on equity of 6.60% beat Genius Sports' return on equity.
Summary
Genius Sports beats Enfusion on 10 of the 18 factors compared between the two stocks.
Get Genius Sports News Delivered to You Automatically
Sign up to receive the latest news and ratings for GENI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GENI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genius Sports Competitors List
Related Companies and Tools
